: In recent years, cancer research has highlighted the role of disrupted microbiota in carcinogenesis and cancer recurrence. However, microbiota may also interfere with drug metabolism, influencing the efficacy of cancer drugs, especially immunotherapy, and modulating the onset of adverse events. Intestinal micro-organisms can be altered by external factors, such as use of antibiotics, proton pump inhibitors treatment, lifestyle and the use of prebiotics or probiotics. The aim of our review is to provide a picture of the current evidence about preclinical and clinical data of the role of gut and local microbiota in malignancies and its potential clinical role in cancer treatments. Standardization of microbiota sequencing approaches and its modulating strategies within prospective clinical trials could be intriguing for two aims: first, to provide novel potential biomarkers both for early cancer detection and for therapeutic effectiveness; second, to propose personalized and "microbiota-tailored" treatment strategies.

Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications

Valsecchi, Anna Amela;Ferrari, Giorgia;Paratore, Chiara;Dionisio, Rossana;Vignani, Francesca;Sperone, Paola;Novello, Silvia;Di Maio, Massimo
2024-01-01

Abstract

: In recent years, cancer research has highlighted the role of disrupted microbiota in carcinogenesis and cancer recurrence. However, microbiota may also interfere with drug metabolism, influencing the efficacy of cancer drugs, especially immunotherapy, and modulating the onset of adverse events. Intestinal micro-organisms can be altered by external factors, such as use of antibiotics, proton pump inhibitors treatment, lifestyle and the use of prebiotics or probiotics. The aim of our review is to provide a picture of the current evidence about preclinical and clinical data of the role of gut and local microbiota in malignancies and its potential clinical role in cancer treatments. Standardization of microbiota sequencing approaches and its modulating strategies within prospective clinical trials could be intriguing for two aims: first, to provide novel potential biomarkers both for early cancer detection and for therapeutic effectiveness; second, to propose personalized and "microbiota-tailored" treatment strategies.
2024
Mar 13
1
18
Biomarker; Cancers; Immune checkpoint inhibitors; Immunotherapy; Microbiota
Valsecchi, Anna Amela; Ferrari, Giorgia; Paratore, Chiara; Dionisio, Rossana; Vignani, Francesca; Sperone, Paola; Vellani, Giorgio; Novello, Silvia; D...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842824000714-main.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 673.67 kB
Formato Adobe PDF
673.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1962794
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact